Complications ‐ DVT · participants with varicose veinsb
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Residual varicose veins · participants with varicose veinsb
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · participants with varicose veinsb
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistence of symptoms · participants with varicose veinsb
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent varicose veins · participants with varicose veinsb
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Duration of total antibiotic therapy ‐ not reported · people with pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood lossTime point: mean 48 hours, range 1 to 13 days. Higher blood loss indicates a worse outcome. · people undergoing total knee replacement
1 finding from 1 review
Pain at post‐operative day 2Scale from 0 (best) to 10 (worst). · people undergoing total knee replacement
1 finding from 1 review
Transfusion rate · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes transfusion rate compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
Range of motion at discharge Scale from: 0 to 125. · people undergoing total knee replacement
1 finding from 1 review
Function Standardised scale with positive score indicating a better outcome. Scale from 0 (worst) to 100 (best). · people undergoing total knee replacement
1 finding from 1 review
Adverse events Adverse events included discomfort, local skin reactions, superficial infections, cold induced injuries and thrombolytic events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes total adverse eventsAdverse events included discomfort, local skin… compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
Fatigue · men and women aged over 18 years with chronic fatigue syndrome
2 findings from 1 review
Participants with serious adverse reactions · men and women aged over 18 years with chronic fatigue syndrome
It is very uncertain whether exercise therapy changes participants with serious adverse reactions Measured after 52 weeks… compared with adaptive pacing therapy (very low certainty).
1 finding from 1 review